In addition, the SSX2 interacting protein (SSX2IP) has been found to be a marker of improved survival in AML patients who had no cytogenetic aberrations [72], while also being elevated in patients with t(15;17), associated with poor prognosis until the advent of (treatment) and decreased in patients harbouring the more favourable t(8;21) [73]. Here, SSX2IP is linked to acute myeloid leukemia.